8-K: Inspire Medical's Inspire V System Shows Superior Efficacy

Inspire Medical Systems, Inc. announced positive clinical outcomes for its new Inspire V system, demonstrating superior efficacy, improved safety, and reduced surgical times for obstructive sleep apnea patients.

Summary

• Inspire Medical Systems, Inc. published clinical outcomes data for its Inspire V system from a Singapore clinical study and a U.S. limited market release.
• The data was presented at the American Otolaryngology-Head and Neck Surgery (AAO-HNS) and International Surgical Sleep Society (ISSS) meetings in Indianapolis from October 9 to October 14, 2025.
• The Inspire V system, building on 25 years of experience and over 100,000 patients implanted with Inspire therapy, features an integrated respiratory sensor, eliminating the need for a separate pressure sensing lead.
• In the Singapore study (44 patients), surgeons achieved a 20% reduction in surgical times compared to Inspire IV cases, with 100% successful procedures.
• The Inspire V device demonstrated superior inspiratory phase overlap percentage (IPOP) of 87.1% compared to 79.4% for Inspire IV.
• Patient adherence in the Singapore study averaged 5.5 ± 1.7 hours/night at a mean of 246 days post-implant.
• Median Apnea Hypopnea Index (AHI) for 37 patients in Singapore reduced from 34.4 events/hour at baseline to 8.3 events/hour at month six.
• The U.S. limited market release (101 patients at 10 centers) reported 100% successful implants with no serious adverse events.
• At the 60-day check, all 101 U.S. patients were using therapy with an average usage of 6.8 hours/night.
• For the first 34 U.S. patients, median AHI reduced from 30 to 4.5 events/hour, with consistent therapy adherence of 6.7 hours/night.
• Proposed 2026 Medicare reimbursement changes include an increase in hospital implant reimbursement from $30,473.59 to $31,751.65 and an increase in Inspire V physician payment (CPT code 64568) from $593.56 to $660.33.

Sentiment

Score: 9

Explanation: The filing presents overwhelmingly positive clinical data for the new Inspire V system, demonstrating superior efficacy, improved safety, reduced surgical times, and high patient adherence. The operational efficiencies and favorable proposed reimbursement changes further enhance the positive outlook, indicating strong potential for market adoption and financial performance.

Positives

• Inspire V system demonstrated superior respiratory sensing (IPOP of 87.1% vs 79.4% for Inspire IV).
• Surgical times were reduced by 20.4% with Inspire V compared to Inspire IV.
• 100% successful implant procedures were reported in both the Singapore study and U.S. limited market release.
• High patient adherence to therapy was observed, averaging 5.5-6.8 hours/night.
• Significant reduction in Apnea Hypopnea Index (AHI) was achieved, with median AHI dropping from 34.4 to 8.3 events/hour in Singapore and 30 to 4.5 events/hour in the U.S.
• The safety profile was strong, with no serious adverse events in the U.S. limited market release and only minor, resolved issues in the Singapore study.
• The simplified procedure, with an integrated respiratory sensor, eliminates a component and incision, enhancing patient comfort and surgical efficiency.
• Increased surgical capacity was noted, with one center performing 12 implants per surgery day with Inspire V compared to 9 with Inspire IV.
• Proposed 2026 Medicare reimbursement for hospital implants and Inspire V physician payments are set to increase.

Future Outlook

The company anticipates continued strong performance and adoption of the Inspire V system, leveraging its superior efficacy, enhanced safety, and simplified procedure. The positive clinical data is expected to support further market penetration and improved patient outcomes. Future data from the Singapore study will be submitted for publication once all patients complete their six-month visits. The proposed Medicare reimbursement changes for 2026 are expected to positively impact the financial landscape for Inspire V procedures.

Management Comments

• Tim Herbert, Chairman and Chief Executive Officer: "We are incredibly excited to publish first-time clinical evidence on the Inspire V system. The design of the Inspire V system captures experience built over 25 years with Inspire therapy including over 100,000 patients implanted, and we are proud to provide the initial data from this advanced platform. Our initial experience raises the bar for what a successful therapy needs to achieve for both safety and efficacy."
• Paul Hoff, M.D., M.S., Vice President, Senior Medical Director: "The strong safety, superior respiratory sensing, and increased adherence, combined with a 20% reduction in surgical times and features designed to enhance patient comfort, demonstrate a truly significant advancement with the Inspire V system."

Industry Context

The announcement positions Inspire Medical Systems as a leader in innovative, minimally invasive solutions for obstructive sleep apnea (OSA), a widespread condition. The Inspire V system's advancements, particularly the integrated respiratory sensor and reduced surgical times, address key challenges in medical device adoption and patient care. The focus on superior efficacy and patient comfort aligns with broader trends in healthcare towards less invasive, more effective, and patient-centric treatments. The positive reimbursement outlook further strengthens the company's competitive position in the sleep apnea treatment market.

Comparison to Industry Standards

• The Inspire V system demonstrates superiority over the previous generation Inspire IV system, with an Inspiratory Phase Overlap Percent (IPOP) of 87.1% for Inspire V compared to 79.4% for Inspire IV.
• Surgical implant times for Inspire V were reduced by 20.4% compared to Inspire IV, with one site reporting average surgical implant times of 34.5 minutes for standard Inspire V placement.
• The simplified two-component, two-incision design of Inspire V offers a less invasive approach compared to the three-component, two or three-incision design of Inspire IV, and potentially other hypoglossal nerve stimulation (HGNS) systems that may require an anterior chest incision.
• Increased surgical capacity, with one center performing 12 implants per surgery day with Inspire V versus 9 with Inspire IV, indicates improved operational efficiency compared to prior generations.

Stakeholder Impact

• Shareholders: Positive clinical data, operational efficiencies, and favorable reimbursement outlook are likely to enhance investor confidence and potentially increase share value.
• Patients: The Inspire V system offers improved efficacy, enhanced comfort features, and a less invasive procedure, leading to better treatment outcomes and quality of life for those with obstructive sleep apnea.
• Surgeons/Healthcare Providers: Reduced surgical times and a simplified procedure can increase surgical capacity and efficiency, while the SleepSync platform aids in patient management. Favorable reimbursement changes are also beneficial.
• Employees: Continued innovation and market success could lead to job stability and growth opportunities within the company.

Next Steps

• Remaining patients in the Singapore study will complete their six-month clinical visits.
• Data from the Singapore study will be submitted for publication once all patient visits are complete.
• The Center for Medicare Services (CMS) is expected to provide final approval for the proposed 2026 Medicare payment changes in November 2025.

Key Dates

Recommendation

The filing provides compelling evidence of the Inspire V system's superior clinical performance, including enhanced efficacy, improved safety, and significant reductions in surgical time. These advancements are expected to drive increased adoption, expand market share, and improve operational efficiencies. Coupled with favorable proposed Medicare reimbursement increases, the company is well-positioned for strong revenue growth and profitability. The positive data and strategic advantages warrant a 'strong buy' recommendation for long-term investors.

Keywords

Obstructive Sleep Apnea, Inspire V, Neurostimulation, Medical Device, Sleep Apnea Treatment, Hypoglossal Nerve Stimulation, Clinical Data, Surgical Time, Patient Adherence, AHI, IPOP, Reimbursement, FDA Approved